D2G ONCOLOGY, INC.
Palo Alto, CA · Founded 2018 · CIK 0001804747 · Biotech · Private
Tumor barcoding and sequencing (Tuba-seq) platform with CRISPR/Cas9-integrated mouse models for pharmacogenomic drug screening
d2g-oncology.com →- Grants
- $2.9M
- 2 awards
- Sector median: 1
- Raised
- $6.6M
- 1 Form D · Feb 2020
- 79 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 7
- 0 granted · 7 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓2019202020212022
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $6,574,998 | |
| Federal grant | Department of Health and Human Services · Phase II · Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform | $1,999,557 | |
| Federal grant | Department of Health and Human Services · Phase II · Relating Drugs to Genotypes to Transform Precision Cancer Therapeutics with Tuba-seq - a Novel, Highly Scalable and Quantitative Preclinical Experimental Oncology Platform | $865,070 |
Federal grant · SBIR/STTRForm D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1889 | Cotinga Pharmaceuticals Inc. | — | $3.0M |
| 1890 | Antlia Bioscience, Inc. | — | $6.9M |
| 1891 | PLEOPHARMA, INC. | — | $17M |
| 1892 | D2G ONCOLOGY, INC. | — | $6.6M |
| 1893 | OCATA THERAPEUTICS, INC. | — | — |
| 1894 | CELLECTAR, Inc. | — | $2.7M |
| 1895 | SUNNYLIFE PHARMA INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Kathleen LaPorteDirector
- Kathy LaPorteDirector
- Jonathan MacQuittyDirector · Executive Officer
- Dmitri PetrovDirector
- Monte WinslowDirector
Patents
- Biomarkers For Predicting Responsiveness To Mek Inhibitor Monotherapy And Combination Therapyapplication
- Biomarkers For Predicting Responsiveness To SHP2 Inhibitor Therapyapplication
- Biomarkers For Predicting Responsiveness To Immune Checkpoint Inhibitor Therapyapplication
- Biomarkers For Predicting Responsiveness To SHP2 Inhibitor Therapyapplication
- Biomarkers For Predicting Responsiveness To Mek Inhibitor Monotherapy And Combination Therapyapplication
- Biomarkers For Predicting Responsiveness To SHP2 Inhibitor Therapyapplication
- Biomarkers For Predicting Responsiveness To Mek Inhibitor Monotherapy And Combination Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.